| Dr Michael L Shoemaker, MD | |
|
1703 W Stones Crossing Rd Ste 200, Greenwood, IN 46143 | |
| (317) 859-3737 | |
| Not Available |
| Full Name | Dr Michael L Shoemaker |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1703 W Stones Crossing Rd Ste 200, Greenwood, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164490215 | NPI | - | NPPES |
| 200288580 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01031183A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael L Shoemaker, MD Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Dr Michael L Shoemaker, MD 1703 W Stones Crossing Rd Ste 200, Greenwood, IN 46143 Ph: (317) 859-3737 |
News Archive
Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF's KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology's research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.
An enzyme researchers have studied for years because of its potential connections to cancer, diabetes, heart disease, hypertension and stroke, appears to have yet another major role to play: helping create and maintain the brain.
› Verified 7 days ago
Dr. Elise Rose Laroche, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 747 E County Line Rd Ste D, Greenwood, IN 46143 Phone: 317-888-9669 Fax: 317-885-7966 | |
Brittany Y. Simpson, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 533 E County Line Rd, Greenwood, IN 46143 Phone: 317-957-9050 | |
Dr. Charles L Richert, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3000 S State Road 135 Ste 220, Greenwood, IN 46143 Phone: 317-621-2290 | |
Dr. Douglas K Bullington, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3000 S State Road 135, Suite 200, Greenwood, IN 46143 Phone: 317-535-1876 Fax: 317-535-5049 | |
Shelley R Stiner, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 107 N State Road 135, Ste 103, Greenwood, IN 46142 Phone: 317-550-4510 Fax: 317-886-4550 | |
Ehab Wanas, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E County Line Rd, Suite 101, Greenwood, IN 46143 Phone: 317-885-2860 Fax: 317-885-2869 | |
Sarah Ann Beeson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3000 S State Road 135 Ste 200, Greenwood, IN 46143 Phone: 317-535-1876 |